{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:50:44Z","timestamp":1791899444848,"version":"4.3.4"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23 DA053507"],"award-info":[{"award-number":["K23 DA053507"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018646","name":"Division of Bone and Mineral Diseases, John T. Milliken Department of Medicine, Washington University in St. Louis","doi-asserted-by":"publisher","award":["R01 DA057566-01"],"award-info":[{"award-number":["R01 DA057566-01"]}],"id":[{"id":"10.13039\/100018646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005386","name":"American Psychiatric Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005386","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007930","name":"Institute of Clinical and Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002345"],"award-info":[{"award-number":["UL1 TR002345"]}],"id":[{"id":"10.13039\/100007930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32 DA015035"],"award-info":[{"award-number":["T32 DA015035"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K12 DA041449"],"award-info":[{"award-number":["K12 DA041449"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.dadr.2023.100195","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T12:02:58Z","timestamp":1697803378000},"page":"100195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6595-695X","authenticated-orcid":false,"given":"Kevin Y","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Robin","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin E","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Bazazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Grucza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dadr.2023.100195_bib0001","series-title":"Criteria Assessment Interview Guide","year":"2023"},{"issue":"9","key":"10.1016\/j.dadr.2023.100195_bib0002","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1176\/appi.ajp.2010.09101406","article-title":"Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder","volume":"167","author":"Bowie","year":"2010","journal-title":"Am. J. Psychiat."},{"issue":"6","key":"10.1016\/j.dadr.2023.100195_bib0003","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/ajad.12784","article-title":"Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial","volume":"27","author":"Campbell","year":"2018","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.dadr.2023.100195_bib0004","article-title":"On intersectionality: essential writings","volume":"255","author":"Crenshaw","year":"2017"},{"issue":"6","key":"10.1016\/j.dadr.2023.100195_bib0005","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/L15-0524","article-title":"The integration of care for mental health, substance abuse, and other behavioral health conditions into primary care in response","volume":"164","author":"Crowley","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.dadr.2023.100195_bib0006","article-title":"Psychiatric comorbidities of substance use disorders: does dual diagnosis predict inpatient detoxification treatment outcomes?","author":"Davis","year":"2022","journal-title":"Int. J. Ment. Health Ad."},{"issue":"3","key":"10.1016\/j.dadr.2023.100195_bib0007","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40596-021-01431-0","article-title":"Addiction teaching and training in the general psychiatry setting","volume":"46","author":"DeJong","year":"2022","journal-title":"Acad. Psychiatr."},{"key":"10.1016\/j.dadr.2023.100195_bib0008","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-015-0942-4","article-title":"Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria","volume":"16","author":"Dennis","year":"2015","journal-title":"Trials"},{"key":"10.1016\/j.dadr.2023.100195_bib0009","article-title":"Impact of alternative ways to operationalize buprenorphine treatment duration on understanding continuity of care for opioid use disorder","author":"Dong","year":"2022","journal-title":"Int. J. Ment. Health Ad."},{"issue":"2","key":"10.1016\/j.dadr.2023.100195_bib0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/ADM.0000000000000726","article-title":"Associations between polysubstance use patterns and receipt of medications for opioid use disorder among adults in treatment for opioid use disorder","volume":"15","author":"Ford","year":"2021","journal-title":"J. Addict. Med."},{"issue":"3","key":"10.1016\/j.dadr.2023.100195_bib0011","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/aje\/kwz158","article-title":"Win-Win: reconciling social epidemiology and causal inference","volume":"189","author":"Galea","year":"2020","journal-title":"Am. J. Epidemiol."},{"issue":"7","key":"10.1016\/j.dadr.2023.100195_bib0012","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/add.15862","article-title":"Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study","volume":"117","author":"Gomes","year":"2022","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.dadr.2023.100195_bib0013","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1176\/appi.ps.202100661","article-title":"Reliability of the term \"serious mental illness\": a systematic review","volume":"73","author":"Gonzales","year":"2022","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.dadr.2023.100195_bib0014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/JCP.1006e12","article-title":"Cognitive impairment and functional outcome in schizophrenia and bipolar disorder","volume":"67","author":"Green","year":"2006","journal-title":"J. Clin. Psychiat."},{"key":"10.1016\/j.dadr.2023.100195_bib0015","article-title":"An investigation of quantitative methods for assessing intersectionality in health research: a systematic review","volume":"16","author":"Guan","year":"2021","journal-title":"Ssm-Popul. Hlth."},{"issue":"6","key":"10.1016\/j.dadr.2023.100195_bib0016","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","article-title":"Policy pathways to address provider workforce barriers to buprenorphine treatment","volume":"54","author":"Haffajee","year":"2018","journal-title":"Am. J. Prev. Med."},{"issue":"10","key":"10.1016\/j.dadr.2023.100195_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.29409","article-title":"Trends in and characteristics of buprenorphine misuse among adults in the US","volume":"4","author":"Han","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"10324","key":"10.1016\/j.dadr.2023.100195_bib0018","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(21)02252-2","article-title":"Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission","volume":"399","author":"Humphreys","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.dadr.2023.100195_bib0019","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1017\/S1092852900019714","article-title":"Anxiety and schizophrenia: the interaction of subtypes of anxiety and psychotic symptoms","volume":"10","author":"Huppert","year":"2005","journal-title":"CNS Spectr."},{"issue":"3","key":"10.1016\/j.dadr.2023.100195_bib0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/aje\/kwz199","article-title":"Invited commentary: making causal inference more social and (social) epidemiology more causal","volume":"189","author":"Jackson","year":"2020","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.dadr.2023.100195_bib0021","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.drugalcdep.2018.12.030","article-title":"Co-occurring substance use and mental disorders among adults with opioid use disorder","volume":"197","author":"Jones","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.dadr.2023.100195_bib0022","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.drugalcdep.2018.12.030","article-title":"Co-occurring substance use and mental disorders among adults with opioid use disorder","volume":"197","author":"Jones","year":"2019","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.dadr.2023.100195_bib0023","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"J. Addict. Med."},{"issue":"29","key":"10.1016\/j.dadr.2023.100195_bib0024","doi-asserted-by":"crossref","first-page":"940","DOI":"10.15585\/mmwr.mm7129e2","article-title":"Drug overdose deaths, by selected sociodemographic and social determinants of health characteristics-25 states and the district of Columbia, 2019-2020","volume":"71","author":"Kariisa","year":"2022","journal-title":"Mmwr-Morbid. Mortal W"},{"issue":"3","key":"10.1016\/j.dadr.2023.100195_bib0025","doi-asserted-by":"crossref","first-page":"E864","DOI":"10.9778\/cmajo.20200190","article-title":"A cross-sectional survey on buprenorphine-naloxone practice and attitudes in 22 Canadian emergency physician groups: a cross-sectional survey","volume":"9","author":"Kestler","year":"2021","journal-title":"CMAJ Open"},{"key":"10.1016\/j.dadr.2023.100195_bib0026","article-title":"What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size","volume":"3","author":"Keyes","year":"2022","journal-title":"Drug Alcohol Depend. Rep."},{"key":"10.1016\/j.dadr.2023.100195_bib0027","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.drugalcdep.2017.02.006","article-title":"The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a US national sample","volume":"175","author":"Krawczyk","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.dadr.2023.100195_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108799","article-title":"Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018","volume":"225","author":"Krebs","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.dadr.2023.100195_bib0029","doi-asserted-by":"crossref","first-page":"sgaa007","DOI":"10.1093\/schizbullopen\/sgaa007","article-title":"Psychosis and comorbid opioid use disorder: characteristics and outcomes in opioid substitution therapy","volume":"1","author":"Lamont","year":"2020","journal-title":"Schizophr. Bull. Open"},{"issue":"2","key":"10.1016\/j.dadr.2023.100195_bib0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00005053-199302000-00003","article-title":"Rehabilitation for adults with severe mental-illness and substance use disorders - a clinical-trial","volume":"181","author":"Lehman","year":"1993","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.dadr.2023.100195_bib0031","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jad.2020.04.056","article-title":"Prevalence of comorbid depression in schizophrenia: a meta -analysis of observational studies","volume":"273","author":"Li","year":"2020","journal-title":"J. Affect. Disorders"},{"issue":"1","key":"10.1016\/j.dadr.2023.100195_bib0032","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/add.15116","article-title":"Polysubstance use and association with opioid use disorder treatment in the US veterans health administration","volume":"116","author":"Lin","year":"2021","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.dadr.2023.100195_bib0033","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/ajad.12644","article-title":"The impact of mental health comorbidities on adherence to buprenorphine: a claims based analysis","volume":"26","author":"Litz","year":"2017","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.dadr.2023.100195_bib0034","article-title":"Individual-level risk prediction of return to use during opioid use disorder treatment","author":"Luo","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.dadr.2023.100195_bib0035","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/add.16190","article-title":"Commentary on Nowakowski et\u00a0al.: bringing the participants\u2019 own words into addictions research\u2014A win\u2013win for patients and investigators","volume":"118","author":"Martin","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2023.100195_bib0036","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsat.2019.07.010","article-title":"Prescribing decisions at buprenorphine treatment initiation: do they matter for treatment discontinuation and adverse opioid-related events?","volume":"105","author":"Meinhofer","year":"2019","journal-title":"J. Subst. Abuse Treat."},{"issue":"1","key":"10.1016\/j.dadr.2023.100195_bib0037","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1186\/s12889-020-09856-2","article-title":"A comprehensive multivariate model of biopsychosocial factors associated with opioid misuse and use disorder in a 2017-2018 United States national survey","volume":"20","author":"Montiel Ishino","year":"2020","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.dadr.2023.100195_bib0038","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-020-00396-x","article-title":"A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data","volume":"17","author":"Morin","year":"2020","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.dadr.2023.100195_bib0039","series-title":"Medications For Opioid Use Disorder Save Lives","article-title":"Engineering, and medicine; health and medicine division; board on health sciences policy; committee on medication-assisted treatment for opioid use disorder","year":"2019"},{"issue":"3","key":"10.1016\/j.dadr.2023.100195_bib0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment","volume":"36","author":"Netherland","year":"2009","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.dadr.2023.100195_bib0041","series-title":"NIMHD Research Framework","year":"2018"},{"key":"10.1016\/j.dadr.2023.100195_bib0042","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jsat.2018.12.006","article-title":"Behavioral health treatment utilization among individuals with co-occurring opioid use disorder and mental illness: evidence from a national survey","volume":"98","author":"Novak","year":"2019","journal-title":"J. Subst. Abuse Treat."},{"issue":"3","key":"10.1016\/j.dadr.2023.100195_bib0043","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1176\/appi.ps.202000818","article-title":"Opioid use disorder among clients of community mental health clinics: prevalence, characteristics, and treatment willingness","volume":"73","author":"Ober","year":"2022","journal-title":"Psychiat. Serv."},{"key":"10.1016\/j.dadr.2023.100195_bib0044","article-title":"An exploratory study of sex and gender differences in demographic, psychosocial, clinical, and substance use treatment characteristics of patients in outpatient opioid use disorder treatment with buprenorphine","author":"Parlier-Ahmad","year":"2021","journal-title":"Trans. Issues Psychol. Sci."},{"key":"10.1016\/j.dadr.2023.100195_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109337","article-title":"Short communication: relationship between social determinants and opioid use disorder treatment outcomes by gender","volume":"232","author":"Parlier-Ahmad","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"9878","key":"10.1016\/j.dadr.2023.100195_bib0046","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(13)60989-7","article-title":"Bipolar Disorder 2 Bipolar disorder diagnosis: challenges and future directions","volume":"381","author":"Phillips","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.dadr.2023.100195_bib0047","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/ADM.0000000000000673","article-title":"Recommended use of terminology in addiction medicine","volume":"15","author":"Saitz","year":"2021","journal-title":"J. Addict. Med."},{"issue":"8","key":"10.1016\/j.dadr.2023.100195_bib0048","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jamapediatrics.2017.1269","article-title":"Closing the medication-assisted treatment gap for youth with opioid use disorder","volume":"171","author":"Saloner","year":"2017","journal-title":"Jama Pediatr."},{"key":"10.1016\/j.dadr.2023.100195_bib0049","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.dadr.2023.100195_bib0050","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis","volume":"78","author":"Santo","year":"2022","journal-title":"Jama Psychiat."},{"issue":"7","key":"10.1016\/j.dadr.2023.100195_bib0051","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1176\/appi.ajp.2021.21060558","article-title":"Dismantling structural racism in psychiatry: a path to mental health equity","volume":"178","author":"Shim","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.dadr.2023.100195_bib0052","article-title":"A systematic review of misdiagnosis in those with obsessive-compulsive disorder","volume":"6","author":"Stahnke","year":"2021","journal-title":"J. Affect. Disord. Rep."},{"issue":"1\u20133","key":"10.1016\/j.dadr.2023.100195_bib0053","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drugalcdep.2011.10.016","article-title":"The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone","volume":"123","author":"Stein","year":"2012","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.dadr.2023.100195_bib0054","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/da.20699","article-title":"Should Ocd be classified as an anxiety disorder in Dsm-V?","volume":"27","author":"Stein","year":"2010","journal-title":"Depress. Anxiety"},{"issue":"4","key":"10.1016\/j.dadr.2023.100195_bib0055","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s11920-011-0207-1","article-title":"Meta-structure issues for the DSM-5: how do anxiety disorders, obsessive-compulsive and related disorders, PTSD, and dissociative disorders fit together?","volume":"13","author":"Stein","year":"2011","journal-title":"Curr. Psychiat. Rep."},{"issue":"12","key":"10.1016\/j.dadr.2023.100195_bib0056","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3109\/10826084.2015.1023455","article-title":"Psychiatric comorbidity and substance use outcomes in an office-based buprenorphine program six months following hurricane sandy","volume":"50","author":"Tofighi","year":"2015","journal-title":"Subst. Use Misuse"},{"issue":"1","key":"10.1016\/j.dadr.2023.100195_bib0057","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1940-0640-9-3","article-title":"Outcomes among buprenorphine-naloxone primary care patients after Hurricane Sandy","volume":"9","author":"Tofighi","year":"2014","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.dadr.2023.100195_bib0058","doi-asserted-by":"crossref","first-page":"n787","DOI":"10.1136\/bmj.n787","article-title":"Is PTSD overdiagnosed?","volume":"373","author":"Tully","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.dadr.2023.100195_bib0059","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1176\/appi.ajp.2019.19121284","article-title":"Personalizing the treatment of substance use disorders","volume":"177","author":"Volkow","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"13","key":"10.1016\/j.dadr.2023.100195_bib0060","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/s41386-021-01069-4","article-title":"Choosing appropriate language to reduce the stigma around mental illness and substance use disorders","volume":"46","author":"Volkow","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.dadr.2023.100195_bib0061","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1081\/ADA-200037538","article-title":"Prevalence and characteristics of clients with co-occurring disorders in outpatient substance abuse treatment","volume":"30","author":"Watkins","year":"2004","journal-title":"Am. J. Drug Alcohol Ab."},{"issue":"2","key":"10.1016\/j.dadr.2023.100195_bib0062","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","volume":"177","author":"Williams","year":"2020","journal-title":"Am. J. Psychiat."},{"issue":"2","key":"10.1016\/j.dadr.2023.100195_bib0063","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s11524-014-9866-7","article-title":"Psychiatric comorbidity, red flag behaviors, and associated outcomes among office-based buprenorphine patients following Hurricane Sandy","volume":"91","author":"Williams","year":"2014","journal-title":"J. Urban Health"},{"issue":"6","key":"10.1016\/j.dadr.2023.100195_bib0064","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.12478","article-title":"Association of new perioperative benzodiazepine use with persistent benzodiazepine use","volume":"4","author":"Wright","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.dadr.2023.100195_bib0065","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1176\/appi.ajp.2020.20081174","article-title":"Association between benzodiazepine or Z-drug prescriptions and drug-related poisonings among patients receiving buprenorphine maintenance: a case-crossover analysis","volume":"178","author":"Xu","year":"2021","journal-title":"Am. J. Psychiat."},{"issue":"3","key":"10.1016\/j.dadr.2023.100195_bib0066","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229787","article-title":"Responses among substance abuse treatment providers to the opioid epidemic in the USA: variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16","volume":"15","author":"Yang","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.dadr.2023.100195_bib0067","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am. J. Epidemiol."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724623000653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724623000653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:14:35Z","timestamp":1778933675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724623000653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":67,"alternative-id":["S2772724623000653"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2023.100195","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2023.100195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100195"}}